FUS and amyotrophic lateral sclerosis: A phase III trial of JacifusenTM (NCT04768972), an ASO designed to reduce FUS protein synthesis from FUS mRNA, is ongoing for patients with FUS gene mutations associated with aggressive juvenile forms of ALS [77,78].